glp 1 and gip function How May Enhance the Therapeutic Efficacy of GLP-1? Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis

RNA sequencing analysis revealed the activation of the Wnt/LRP5/-catenin signaling pathway

StoeckelLE,ArvanitakisZ,GandySetal.Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction.F1000Res.2016;5:353

Clinical studies support: It pairs well with glycine (via collagen peptides) to complete the glutathione triad

Some individuals may also consume fewer foods naturally rich in B12, especially if their diet changes significantly

Obes Rev, 17(10), 970-6